scholarly journals Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia

Blood ◽  
2018 ◽  
Vol 131 (9) ◽  
pp. 995-999 ◽  
Author(s):  
Karen L. Bride ◽  
Tiffaney L. Vincent ◽  
Soo-Yeon Im ◽  
Richard Aplenc ◽  
David M. Barrett ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
T Cell ◽  
Lymphoblastic Leukemia ◽  
Key Points ◽  
Cell Acute Lymphoblastic Leukemia ◽  
Xenograft Models ◽  
Preclinical Efficacy ◽  
Novel Target ◽  
Human Xenograft Models

Key Points Daratumumab is effective against T-ALL in human xenograft models. CD38 is a novel target with broad potential in the treatment of T-ALL.

PTEN microdeletions in T-cell acute lymphoblastic leukemia are caused by illegitimate RAG-mediated recombination events

Blood ◽  
2014 ◽  
Vol 124 (4) ◽  
pp. 567-578 ◽  
Author(s):  
Rui D. Mendes ◽  
Leonor M. Sarmento ◽  
Kirsten Canté-Barrett ◽  
Linda Zuurbier ◽  
Jessica G. C. A. M. Buijs-Gladdines ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
T Cell ◽  
Lymphoblastic Leukemia ◽  
Human T Cell ◽  
Key Points ◽  
Inactivation Mechanism ◽  
Cell Acute Lymphoblastic Leukemia

Key Points Microdeletions represent an additional inactivation mechanism for PTEN in human T-cell acute lymphoblastic leukemia. PTEN microdeletions are RAG-mediated aberrations.

scholarly journals Homeobox protein TLX3 activates miR-125b expression to promote T-cell acute lymphoblastic leukemia

2017 ◽  
Vol 1 (12) ◽  
pp. 733-747 ◽  
Author(s):  
Laurent Renou ◽  
Pierre-Yves Boelle ◽  
Caroline Deswarte ◽  
Salvatore Spicuglia ◽  
Aissa Benyoucef ◽  
...  
Keyword(s):  
T Cells ◽  
Acute Lymphoblastic Leukemia ◽  
T Cell ◽  
Lymphoblastic Leukemia ◽  
Host Gene ◽  
Key Points ◽  
Homeobox Protein ◽  
Cell Acute Lymphoblastic Leukemia

Key Points TLX3 transactivates LINC00478, the host gene of oncogenic miR-125b-2 in T-ALL. TLX3 and miR-125b contribute to the differentiation arrest and the expansion of transformed T cells.

scholarly journals Bone marrow sites differently imprint dormancy and chemoresistance to T-cell acute lymphoblastic leukemia

2017 ◽  
Vol 1 (20) ◽  
pp. 1760-1772 ◽  
Author(s):  
Xavier Cahu ◽  
Julien Calvo ◽  
Sandrine Poglio ◽  
Nais Prade ◽  
Benoit Colsch ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Acute Lymphoblastic Leukemia ◽  
T Cell ◽  
Lymphoblastic Leukemia ◽  
Key Points ◽  
Cell Acute Lymphoblastic Leukemia

Key Points BM niches differentially support T-ALL. BM niches differentially protect T-ALL cells from chemotherapy.

scholarly journals Deletion of Pten in CD45-expressing cells leads to development of T-cell lymphoblastic lymphoma but not myeloid malignancies

Blood ◽  
2016 ◽  
Vol 127 (15) ◽  
pp. 1907-1911 ◽  
Author(s):  
Cristina Mirantes ◽  
Maria Alba Dosil ◽  
David Hills ◽  
Jian Yang ◽  
Núria Eritja ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
T Cell ◽  
Mouse Model ◽  
Lymphoblastic Leukemia ◽  
Hematopoietic Cells ◽  
Hematologic Malignancies ◽  
Lymphoblastic Lymphoma ◽  
Key Points ◽  
Pten Deletion ◽  
Cell Acute Lymphoblastic Leukemia

Key Points CD45-driven expression of Cre generates the first mouse model that allows specific and exclusive deletion of Pten in hematopoietic cells. Pten deletion in CD45-expressing cells causes T-cell acute lymphoblastic leukemia, but no other hematologic malignancies.

scholarly journals Prognostic relevance of integrated genetic profiling in adult T-cell acute lymphoblastic leukemia

Blood ◽  
2013 ◽  
Vol 122 (1) ◽  
pp. 74-82 ◽  
Author(s):  
Pieter Van Vlierberghe ◽  
Alberto Ambesi-Impiombato ◽  
Kim De Keersmaecker ◽  
Michael Hadler ◽  
Elisabeth Paietta ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
T Cell ◽  
High Risk ◽  
Lymphoblastic Leukemia ◽  
Poor Response ◽  
Genomic Profiling ◽  
Genetic Profiling ◽  
Key Points ◽  
Cell Acute Lymphoblastic Leukemia ◽  
Intensified Chemotherapy

Key Points Integrated genomic profiling identifies high-risk adult T-ALL patients with poor response to intensified chemotherapy.

scholarly journals Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia

Blood ◽  
2018 ◽  
Vol 131 (3) ◽  
pp. 289-300 ◽  
Author(s):  
Arnaud Petit ◽  
Amélie Trinquand ◽  
Sylvie Chevret ◽  
Paola Ballerini ◽  
Jean-Michel Cayuela ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
T Cell ◽  
Outcome Prediction ◽  
Lymphoblastic Leukemia ◽  
Individual Treatment ◽  
Predictors Of Outcome ◽  
Improve Outcome ◽  
Key Points ◽  
Cell Acute Lymphoblastic Leukemia ◽  
Wbc Count

Key Points In pediatric T-ALL, oncogenetic markers, MRD, and WBC count are independent predictors of outcome. These factors should be used together for individual treatment stratification.

scholarly journals WP1130 reveals USP24 as a novel target in T-cell acute lymphoblastic leukemia

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Hao Luo ◽  
Bo Jing ◽  
Yu Xia ◽  
Yugen Zhang ◽  
Meng Hu ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
T Cell ◽  
Lymphoblastic Leukemia ◽  
Cell Acute Lymphoblastic Leukemia ◽  
Novel Target

scholarly journals Suz12 inactivation cooperates with JAK3 mutant signaling in the development of T-cell acute lymphoblastic leukemia

Blood ◽  
2019 ◽  
Vol 134 (16) ◽  
pp. 1323-1336 ◽  
Author(s):  
Michael Broux ◽  
Cristina Prieto ◽  
Sofie Demeyer ◽  
Marlies Vanden Bempt ◽  
Llucia Alberti-Servera ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
T Cell ◽  
Lymphoblastic Leukemia ◽  
Leukemia Cells ◽  
Vegf Receptor ◽  
Hsp90 Inhibitors ◽  
Key Points ◽  
Increased Sensitivity ◽  
Cell Acute Lymphoblastic Leukemia

Key Points Suz12 inactivation cooperates with JAK3 mutant signaling to drive T-ALL development. JAK3/Suz12 mutant leukemia cells show increased sensitivity to PI3K/mTOR, VEGF receptor, and HSP90 inhibitors.

scholarly journals AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia

Blood ◽  
2015 ◽  
Vol 126 (10) ◽  
pp. 1193-1202 ◽  
Author(s):  
Donya Moradi Manesh ◽  
Jad El-Hoss ◽  
Kathryn Evans ◽  
Jennifer Richmond ◽  
Cara E. Toscan ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Acute Lymphoblastic Leukemia ◽  
T Cell ◽  
Lymphoblastic Leukemia ◽  
Preclinical Models ◽  
Novel Treatment ◽  
Key Points ◽  
Cell Acute Lymphoblastic Leukemia

Key Points PR-104 represents a potential novel treatment for relapsed/refractory T-ALL. AKR1C3 expression could be used as a biomarker to select patients who may respond to PR-104 in prospective clinical trials.

scholarly journals Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia

Blood ◽  
2015 ◽  
Vol 125 (11) ◽  
pp. 1759-1767 ◽  
Author(s):  
Shannon L. Maude ◽  
Sibasish Dolai ◽  
Cristina Delgado-Martin ◽  
Tiffaney Vincent ◽  
Alissa Robbins ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
T Cell ◽  
High Risk ◽  
Lymphoblastic Leukemia ◽  
Cell Precursor ◽  
Patient Derived Xenograft ◽  
Key Points ◽  
Xenograft Models ◽  
Pathway Inhibition ◽  
Stat Pathway

Key Points ETP-ALL, a high-risk subtype of T-ALL, is characterized by aberrant activation of the JAK/STAT signaling pathway. The JAK1/2 inhibitor ruxolitinib demonstrates robust activity in patient-derived xenograft models of ETP-ALL.

Sign in / Sign up

Export Citation Format

Share Document